Developing a new therapeutic pipeline to treat metabolic diseases that present global health challenges.
Now advancing our first-in-class drug candidate.
The Challenge of Patients’ Unmet Clinical Needs
Senseion Therapeutics is a preclinical-stage pharmaceutical company developing new medicines to treat metabolic diseases that present global health challenges—specifically those associated with chloride ion channel diseases.
First in our pipeline and under development now is a small molecule therapeutic, SN-40X, to treat metabolic disease.
